Introduction
Kaposi's sarcoma (KS)' is epidemic in HIV-infected individuals. A substantial proportion ofhomosexual males with AIDS ( 15-18%) experience clinical complications due to KS during the course oftheir disease (1) (2) (3) . Autopsy series have shown an even higher prevalence (59-95%) in this group (4, 5) . A growing body of evidence on the growth characteristics of KS cells cultured in vitro indicates the importance of autocrine pathways in regulation of proliferation, including prominent roles played by IL-6, basic fibroblast growth factor(bFGF), Oncostatin M, and PDGF, as well as the HIV-l tat protein (6) (7) (8) (9) (10) (11) (12) (13) (14) . Therapy, including the use of vinca alkaloids, radiotherapy, interferon-alpha, and others, alone and in combination, has been directed towards palliation ofboth cutaneous and visceral disease (15) (16) (17) (18) (19) (20) (21) .
Retinoids are pharmacologic compounds derived from vitamin A (retinol), which plays a critical role in growth, repro-duction, differentiation, and immune response, and may contribute in limiting the growth of certain malignancies. Retinoids have been used in the treatment of a variety of malignancies, including KS, with mixed results (22) (23) (24) (25) (26) . The effects of retinoids are mediated by two families of nuclear retinoic acid receptors (27) (28) (29) (30) (RAR-a, -A, -y and RxRa). Retinoids have been shown to inhibit the growth of human melanoma cell lines by downregulating IL-6 receptors (31), providing a rationale for the investigation of retinoid compounds as therapeutics in KS. Promising results have been obtained with topical monotherapy of KS with tretinoin (32) .
In this laboratory, KS cell (KSC) cultures derived from pleural fluid and cutaneous or mucosal biopsies have been successfully established, including KSC cell cultures from both HIV-positive and -negative individuals. To determine the response of these KSC cultures to retinoids, KSC were treated with graded concentrations of a representative panel of retinoids (tretinoin, isotretinoin, acitretin, and Rol 3-1470), and inhibition of proliferation and cytotoxicity was correlated with the effects of retinoid treatment on IL-6 and bFGF, and their receptors.
Methods
Cell culture. KSC l was obtained from a explant of a biopsy obtained from a young HIV-l-negative homosexual male with KS principally involving the trunk and upper extremities. KSC2, 3, and 4 were obtained from HIV-infected homosexual men by explant from biopsies from cutaneous lesions of disseminated HIV-associated KS. All explants were grown in D-valine (GIBCO BRL, Gaithersburg, MD) DMEM supplemented with 10% endothelial cell-conditioned medium and 1% Condimedam9 (Boeringer Mannheim Biochemicals, Indianapolis, IN). Human umbilical vein endothelial cells (HUVEC) were purchased at passage 2 from Clonetics (San Diego, CA). The smooth muscle cell line SKLMS-I and the fibroblast cell line CCD34Lu were obtained from the American Type Culture Collection (Rockville, MD). For all studies, cells were passaged using an enzymatic preparation capable of releasing the cells from the substratum (Passage-ease; Vectec, Schenectady, NY) and grown in EGM (Clonetics) that contains 2% fetal bovine serum supplemented with epidermal growth factor ( 10 ng/ml), hydrocortisone (1 tg/ml), and a bovine brain extract ( 12 ug/ml) containing heparin (10 ,g/ml) and the antibiotics gentamicin (50 ug/ml) and amphotericin-B (50 ng/ml). Alternatively, the cells were grown in Endothelial-serum-free media (SFM) supplied by GIBCO BRL for the thymidine uptake assay.
Chemicals. Tretinoin (all-trans-retinoic acid); isotretinoin ( 1 3-cisretinoic acid); acitretin ([all-trans-9 (4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid] and RO13-7410 (p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetra methyl-2-naphthyl)-1propenyl] benzoic acid) were obtained from Roche Products (Dee Why, Australia). The compounds were dissolved in DMSO at 10-2 M and diluted in the culture media at the final dilution used. The stock solutions were stored at -70°C protected from light and oxygen.
Apoptosis assay. Treated and controls cells were released from the substratum using Passage-ease and fixed in 30% ethanol in PBS. Propidium iodine (PI) was added for 30 min at a concentration of 50 ,gg/ml in PBS containing 0.1% Triton X-100, 0.1 mM EDTA(Na)2, and RNAse at 50 Mg/ml (50 U/mg). The cells were washed twice in PBS and analyzed in a FACS® (Becton Dickinson & Co., Mountain View, CA) using a cell cycle analysis doublet discrimination protocol (33) .
[3H] Thymidine uptake assay. Cells (KSC, fibroblasts, smooth muscle cells, and HUVEC) were plated in 96-well plates (previously coated with fibronectin for KS and HUVEC) at a density of 3,000-5,000 cells/well. The cells were maintained in endothelial serum-free medium (GIBCO BRL) for the duration of the experiment. Controls included endothelial-SFM, and endothelial-SFM with DMSO added to the same final concentration present in each corresponding dilution of retinoid solution ( 14 mM DMSO for I0-5 retinoid dilutions, 140 ,M DMSO for l0-7 retinoid dilutions, and 1.4 MM DMSO for l0-9 retinoid dilutions). Acitretin, tretinoin, isotretinoin, Ro 13-7410, and DMSO were diluted in endothelial-SFM to obtain concentrations of 10-5, 10-7, and 10 -9 M ofeach retinoid ( 14 mM, 140 MM, and 1.4IM DMSO, respectively), and 200 Ml was added to each well. [3H]thymidine (specific activity, 20 mCi/ml) was added to a final concentration of2 MCi/well (0.2 MCi/ml for the HUVEC). Each experimental condition was assayed in quadruplicate. After 2 d, the cells were rinsed once with M 199 and 200 Ml of a solution of trypsin-EDTA (GIBCO BRL) was added to release the adherent cells from the matrix. The cells were harvested using a Skatron harvester, and the radioactive signal was determined by placing the filters in 5 ml of Ready-Safe cocktail (Beckman Instruments, Fullerton, CA) followed by counting in the tritium channel of a scintillation counter (ICN Micromedic, Huntsville, AL). The resulting counts for each experimental condition were the mean ofquadruplicates. The percentage ofcontrol was obtained by dividing the mean of a condition by the value obtained for the DMSO control without retinoid.
PCR mRNA analysis. Total RNA was isolated by the method of Chomczynski and Sacchi (34) from 3 X 106cells and stored in the form ofan ethanol precipitate at -20°C. For DNase I treatment, 5 Ag oftotal RNA was dissolved in 100 Ml DNase digestion buffer (10 mM Tris-HCl, pH 7.4, 10 mM MgCI2, 1 mM DTT) containing 2 U/Ml RNase free DNase I (Boehringer Mannheim Biochemicals) and 0.4 U/Ml RNasin (Boehringer Mannheim Biochemicals), and incubated for 45 min at 37°C. RNA was extracted once each with phenol followed by phenol-chloroform, and precipitated with ethanol, and resuspended in 12 Ml DEPC-treated distilled water.
Template primer (1 Ml = 500 ng) oligo(dT) 12-18 (Clontech) was added to the RNA (10 Ml) and the sample was heated to 65°C for 5 min, and allowed to cool for 10 min to allow for primer annealing. A final volume of 25 Ml was obtained after the addition of 12 Ml reverse transcriptase buffer (50 mM Tris-HCI, pH 8.3, 75 mM KCI, 3 mM MgCI2, 1 mM DTT) containing 2 U Moloney murine leukemia virus reverse transcriptase (Boehringer Mannheim Biochemicals), 20 U RNasin (Boehringer Mannheim Biochemicals), and 0.6 mM of each deoxyribonucleoside triphosphate (dNTP). The sample was then incubated at 37°C for 1 h. Oligonucleotides were synthesized using a oligosynthesizer (Pharmacia Fine Chemicals, Piscataway, NJ) and deprotected in ammonium hydroxide and ethanol precipitated and washed before aliquoting and freezing at 50 pM/ml. The sequences of the gene-specific primers and the size ofthe segments defined were as follows: IL-6 sense Quantification ofIL-6. IL-6 ELISA was performed on culture supernatants (stored at -800C) as described by the manufacturer (R&D Research, Minneapolis, MN). This assay uses a polyclonal capture antibody and monoclonal antibodies for detection (35) .
Results
The effect of four retinoid compounds on the proliferative response of cultures of three KS cell strains and control cells (endothelial cells, smooth muscle cells, and fibroblasts) was determined by using a standard [3H]thymidine uptake assay.
All of the compounds tested, with the exception of acitretin, inhibited the growth rate ofKSC I by 50-70% at I0-5 M ( Fig. 1  A) . The retinoid effects were negligible at the lower concentrations of l0-7 and 10-9 M. The proliferation rates ofKSC2 (Fig.  1 B) and KSC4 ( Fig. 1 E) were also reduced, but to a lesser extent, ranging from 20 to 90% depending on the compound and concentration assayed. The KSC3 culture ( Fig. 1 C) was sensitive to the action of the retinoids. Both tretinoin and acitretin produced > 90% inhibition ofgrowth at nanomolar concentrations. A stimulatory effect on KSC3 growth was seen at the lowest concentrations tested for two of the compounds (RO13-1470 and isotretinoin). Note that the efficacy of retinoids generally decreased with passage number ofKSC in vitro (see Fig. 1 C, passage 4; and Fig. 1 D, passage 6); therefore, KSC used in subsequent experiments were all used at less than eight in vitro passages.
To approach the question of specificity of inhibition of KSC, the retinoids were also tested for their growth inhibitory capabilities on other cell types. The smooth muscle cell line SKLMS-1 (Fig. 2 A) was inhibited (up to 90%) in a fashion similar to the (less-sensitive) KSC. Primary endothelial cells ( Fig. 2 B) were found to be strongly inhibited by retinoids. In contrast, the fibroblast cell line CCD34lu was refractory to inhibition by the retinoids tested (Fig. 2 C) .
Because retinoids are bound by several serum proteins (36, 37) , the effect of the presence of serum on retinoid action was investigated. FBS had little effect on the inhibition produced by retinoids (not shown); however, growth inhibition produced by tretinoin was reduced from 83 to 35% by addition of 10% heat-inactivated whole human serum to the culture medium. The addition of 10% human serum that had been delipidized using the methylethylketone extraction procedure (38) dye) staining and flow cytometric analysis. While trypan blue was excluded by > 98% of all cell populations, indicating that the membrane was still functionally intact, PI staining revealed a pattern of DNA fragmentation suggestive ofthe induction of programmed cell death in treated KSC. The attached cell population constituted 80% of the treated cells and 100% of the control cells. In both treated and control cell cultures, few attached cells were found to be apoptotic (4% oftreated cells and 3% ofcontrol cells). In the detached cell population, representing 20% of the total treated cells, significantly more cells (22%) were found to display staining characteristic of apoptosis.
The effects ofretinoids on the expression ofmRNA for IL-6 and bFGF as well as their respective receptors were analyzed in an attempt to correlate the growth inhibition with regulation of cytokines and their receptors. Tretinoin at 10' M had no discernible effect on the level of mRNA expression of the bFGF receptor ( Fig. 4 ) at 48 h, and bFGF expression was actually elevated in KSC1 (Fig. 4, lanes 9 ). The pattern of effects on IL-6 messages was slightly more complex. IL-6 expression was clearly enhanced by tretinoin treatment in KSC 1 cultures (Fig.  4, lanes 9 ), but only a marginal increase in IL-6 receptor message was seen between retinoidand DMSO-treated control KSC3 cells (Fig. 4, lanes 5 and 6) . IL-6 receptor expression was decreased in control endothelial cells when treated with tretinoin (Fig. 4, lanes 1-3) . This is made more difficult to interpret in view of the lower constitutive expression of IL-6 receptor in KSC3 cultures (Fig. 4, lanes 4 ), in comparison with KSC1 cells (Fig. 4, lanes 7) .
The level of mRNA for IL-6 as measured by RNA PCR correlated with the protein expression as measured by ELISA ( Fig. 5) . A tretinoin concentration of 10-6 M was used to prevent extensive cell death, although effects on the morphology of the cells could readily be seen at this concentration. An increase in IL-6 production was noted in retinoid-treated KSC 1. This cell culture, derived from an HIV-negative individual, is not a high producer of IL-6, a hallmark of KS cell culture in general. The response of these cells to retinoids, with respect to IL-6 production, appeared to be similar to those of fibroblasts (not shown). The production of IL-6 message in endothelial control cell cultures (HUVEC) was inhibited by the tretinoin treatment, while the constitutive production of IL-6 by KSC3 and KSC4 remained unaffected by retinoid treatment.
Discussion
The present study revealed that some KSC are relatively sensitive to the action of retinoids, while others are no more sensitive to inhibition by retinoids than normal endothelial or smooth muscle cells. Concentrations as low as 10-9 M were sufficient to significantly inhibit the growth of early passage KSC2, a concentration that is pharmacologically achievable with oral systemic therapy. More rapidly dividing early passage KS cells were found to be more sensitive to retinoids, suggesting that KSC may actually be quite susceptible to inhibition by retinoids in vivo. Further studies are needed to more definitively address the effect ofin vitro passage on KS cell responses. Antiproliferative effects observed on endothelial cells (HU-VEC) and the smooth muscle cells (SKMLS-I) may be oflittle consequence therapeutically, as the growth ofthese cells is very tightly regulated in vivo. The lack of effect of retinoid treatment on the growth oflung fibroblasts (CCD34Lu) may be due to differential expression of nuclear retinoid receptors, or an interaction with other specific factor(s) present in these cells. A distinct IL-6 phenotype was observed in KSC3, a KSC derived from an HIV-positive individual, compared with KSC1 (derived from an HIV-negative homosexual man with KS) and KSC4 (derived from an explant ofanother HIV-I -positive individual). The KSC3 culture constitutively produced significantly more IL-6 than KSC1, and while IL-6 expression was increased by retinoid treatment in KSC1, it was slightly reduced in KSC3 cells treated with tretinoin. IL-6 production remained unaffected by tretinoin ( l0-5 M) treatment. This finding suggested the possibility that the importance ofthe IL-6 autocrine pathway might differ between KS cultures derived from different individuals.
The antiproliferative effect of retinoids on KSC did not appear to be mediated by the downregulation of IL-6 or bFGF, two of the main cytokines involved in the pathogenesis of KS (7, 8, 13) . In addition, the analysis of the receptor expression for IL-6 as well as bFGF revealed no alteration by retinoids despite a substantial decrease in proliferative rate. The antiproliferative effects of retinoids may be due to alterations in expression of a number of other cytokines or receptors, possibly including uncoupling of oncostatin M production from the IL-6 autocrine pathway or upregulation of TGF-f,, a natural growth inhibitor of endothelial cell proliferation, or expression ofTGF-,3 receptors (39). Retinoids ( l0-5 M) induced apoptosis in KSC, consistent with induction ofprogrammed cell death by withdrawal of growth factor(s).
A careful correlation ofthe clinical response of KS to treatment with topical or systemic retinoids with in vitro sensitivity would appear to be of value in discerning the mechanism of action of retinoids against KS in vivo. In addition, the efficacy of the treatment might be increased if in vitro testing could identify compounds with a greater potential therapeutic index (specificity for KSC) or compounds that are not inhibited by factors present in plasma or serum. The action of retinoids combined with other drugs in vitro is another area for future investigation that may have therapeutic implications. In this regard, the combination of retinoid treatment with antisense oligodeoxynucleotides directed against IL-6 or bFGF, antiangiogenic agents (e.g., the sulfated polyglycan SPPG), or with certain chemotherapeutic agents such as etoposide or bleomycin (where retinoids have been shown to increase cytotoxicity in RA-sensitive cells, but decrease the efficacy of these drugs in RA-resistant cells (40) may be of interest.
